A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Clinical trial NCT03634540 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03634540
Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer Renal Cancer Renal Cell Carcinoma Renal Cell Cancer Metastatic Renal Cell Carcinoma Recurrent Renal Cell Cancer, Recurrent Kidney

Start date: 2018-09-27
Primary completion: 2027-02-26
Enrollment: 118

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.